Reduction of Sleep-disordered Breathing after Physostigmine

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 10, 2003, Pages 1246-1251

  Hedner, Jan ^a   Kraiczi, Holger ^a   Peker, Yuksel ^a   Murphy, Paul ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acetylcholine; Apnea; Physostigmine; Sleep disordered breathing; Treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; PHYSOSTIGMINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; HEART RATE; HUMAN; MALE; NONREM SLEEP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP APNEA SYNDROME; SLEEP TIME; STEADY STATE; TREATMENT OUTCOME;

ADULT; BODY MASS INDEX; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PHYSOSTIGMINE; POLYSOMNOGRAPHY; SEVERITY OF ILLNESS INDEX; SLEEP APNEA, OBSTRUCTIVE; SLEEP, REM; TIME FACTORS;

EID: 0242636941     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200211-1344OC     Document Type: Article

References (38)

1. Berry RB, Gleeson K. Respiratory arousal from sleep: mechanisms and significance. Sleep 1997;20:654-675.
2. Horner RL. Impact of brainstem sleep mechanisms on pharyngeal motor control. Respir Physiol 2000;119:113-121.
3. Schellenberg JB, Maislin G, Schwab RJ. Physical findings and the risk for obstructive sleep apnea: the importance of oropharyngeal structures. Am J Respir Crit Care Med 2000;162:740-748.
4. Larsson H, Carlsson-Nordlander B, Lindblad LE, Norbeck O, Svanborg E. Temperature thresholds in the oropharynx of patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 1992;146:1246-1249.
5. Friberg D, Ansved T, Borg K, Carlsson-Nordlander B, Larsson H, Svanborg E. Histological indications of a progressive snorers disease in an upper airway muscle. Am J Respir Crit Care Med 1998;157:586-593.
6. Remmers JE, deGroot WJ, Sauerland EK, Anch AM. Pathogenesis of upper airway occlusion during sleep. J Appl Physiol 1978;44:931-938.
7. Younes M. The physiologic basis of central apnea and periodic breathing. Curr Pulmonol 1989;10:265-326.
8. Khoo MCK. Determinants of ventilatory instability and variability. Respir Physiol 2000;122:167-182.
9. Triggle DJ, Mitchell JM, Filler R. The pharmacology of physostigmine. CNS Drug Rev 1998;4:87-136.
10. Buccafusco JJ. The role of central cholinergic neurones in the regulation of blood pressure and in experimental hypertension. Pharmacol Rev 1996;48:179-211.
11. Gillin JC, Sitaram N, Mendelson WB, Wyatt RJ. Physostigmine alters onset but not duration of REM sleep in man. Psychopharmacology (Berl) 1978;58:111-114.
12. Gilman S, Chervin RD, Koeppe RA, Consens FB, Little R, An H, Junck L, Heumann M. Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA. Neurology 2003;61:35-39.
13. Hedner J, Kraiczi H, Murphy P, Peker Y. Reduction of sleep disordered breathing after physostigmine [abstract]. Am J Respir Crit Care Med 2002;165:A725.
14. Rechtshaffen A, Kales A, editors. A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Stages of Human Subjects. Bethesda MD: National Institute of Neurological Diseases and Blindness; 1971. NIH Publication No. 204.
15. American Sleep Disorders Association. EEG arousal: scoring rules and examples. Sleep 1992;15:174-184.
16. Hartvig P, Wiklund L, Lindström B. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiol Scand 1986;30:177-182.
17. Rubnov S, Levy D, Schneider H. Liquid chromatographic analysis of physostigmine salicylate and its degradation products. J Pharm Biomed Anal 1999;18:939-945.
18. Sano M, Bell K, Marder K, Stricks L, Stern Y, Mayeux R. Safety and efficacy of oral physostigmine in the treatment of Alzheimer's disease. Clin Neuropharmacol 1993;16:61-69.
19. Vogler BW. Alternatives in the treatment of memory loss in patients with Alzheimer's disease. Clin Pharm 1991;10:447-456.
20. Somani SM, Unni LK, Khalique A. Time course of physostigmine metabolism in plasma and tissues after i.v. administration. Pharmacologist 1985;27:396.
21. Somani SM. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration. Biopharm Drug Dispos 1989;10: 187-203.
22. Giacobini E, Somani S, McIlhany M, Downen M, Hallak M. Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs. Neuropharmacology 1987;26:831-836.
23. Bartolini A, Bartolini R, Domino EF. Effects of physostigmine on brain acctylcholine content and release. Neuropharmacology 1973;12:15-25.
24. Hallak M, Giacobini E. Relation of brain regional physostigmine concentration to cholinesterase activity and acetylcholine and choline levels in rat. Neurochem Res 1986;11:1037-1048.
25. Nilsson L, Nordberg A, Hardy J, Wester P, Winblad B. Physostigmine restores (3H)acetylcholine efflux from Alzheimer brain slices to normal level. J Neural Transm 1986;67:275-285.
26. Somani SM, Gupta SK, Khalique A, Unni LK. Physiological, pharmacokinetic and pharmacodynamic model of physostigmine in the rat. Drug Metab Dispos 1991;19:655-660.
27. Baghdoyan HA. Location and quantification of muscarinic receptor sub-types in the rat pons: implications for REM sleep generation. Am J Physiol 1997;273:R896-R904.
28. Punjabi NM, Bandeen-Roche K, Marx JJ, Neubauer DN, Smith PL, Schwartz AR. The association between daytime sleepiness and sleep-disordered breathing in NREM and REM sleep. Sleep 2002;25:307-314.
29. Riemann D, Joy D, Hochli D, Lauer C, Zulley J, Berger M. Influence of the cholinergic agonist RS 86 on normal sleep: sex and age effects. Psychiatry Res 1988;24:137-147.
30. O'Donnell CP, Schwartz AR, Smith PL. Upper airway collapsibility: the importance of gender and adiposity. Am J Respir Crit Care Med 2000;162:1606-1607.
31. Bellingham MC, Ireland MF. Contribution of cholinergic systems to state-dependent modulation of respiratory control. Respir Physiol Neurobiol 2002;131:135-144.
32. Burton MD, Kazemi H. Neurotransmitters in central respiratory control. Respir Physiol 2000;122:111-121.
33. Fitzgerald RS, Shirahata M, Wang HY. Acetylcholine is released from in vitro cat carotid bodies during hypoxic stimulation. Adv Exp Med Biol 2000;475:485-494.
34. Haxhiu MA, Cherniack NS, Mitra J, van Lunteren E, Strohl KP. Nonvagal modulation of liypoglossal neural activity. Respiration (Herrlisheim) 1992;59:65-71.
35. Hedner E, Birkhed D, Hedner J, Ekström J, Helander H. Stimulation of minor salivary glands by intraoral treatment with the cholinesterase inhibitor physostigmine in man. Eur J Oral Sci 2001;109:371-374.
36. Jokic R, Klimaszewski A, Mink J, Fitzpatrick MF. Surface tension forces in sleep apnea: the role of a soft tissue lubricant: a randomized double-blind, placebo-controlled trial. Am J Respir Crit Care Med 1998;157: 1522-1525.
37. Garrigue S, Bordier P, Jais P, Shah DC, Hocini M, Raherison C, Tunon De Lara M, Haissaguerre M, Clementy J. Benefit of atrial pacing in sleep apnea syndrome. N Engl J Med 2002;346:404-412.
38. Kass JE, Akers SM, Bartter TC, Pratter MR. Rapid-eye-movement-specific sleep-disordered breathing: a possible cause of excessive day-time sleepiness. Am J Respir Crit Care Med 1996;154:167-169.